AU2004275888B2 - Compounds and compositions as protein kinase inhibitors - Google Patents

Compounds and compositions as protein kinase inhibitors Download PDF

Info

Publication number
AU2004275888B2
AU2004275888B2 AU2004275888A AU2004275888A AU2004275888B2 AU 2004275888 B2 AU2004275888 B2 AU 2004275888B2 AU 2004275888 A AU2004275888 A AU 2004275888A AU 2004275888 A AU2004275888 A AU 2004275888A AU 2004275888 B2 AU2004275888 B2 AU 2004275888B2
Authority
AU
Australia
Prior art keywords
phenyl
naphthalen
imidazol
pyridin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004275888A
Other languages
English (en)
Other versions
AU2004275888A1 (en
Inventor
Nathanael Schiander Gray
Jiqing Jiang
Yi Liu
Ruo Steensma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of AU2004275888A1 publication Critical patent/AU2004275888A1/en
Application granted granted Critical
Publication of AU2004275888B2 publication Critical patent/AU2004275888B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
AU2004275888A 2003-10-02 2004-10-01 Compounds and compositions as protein kinase inhibitors Ceased AU2004275888B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50845003P 2003-10-02 2003-10-02
US60/508,450 2003-10-02
PCT/US2004/032597 WO2005030151A2 (fr) 2003-10-02 2004-10-01 Composes et compositions utiles comme inhibiteurs de la proteine kinase

Publications (2)

Publication Number Publication Date
AU2004275888A1 AU2004275888A1 (en) 2005-04-07
AU2004275888B2 true AU2004275888B2 (en) 2008-09-18

Family

ID=34393249

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004275888A Ceased AU2004275888B2 (en) 2003-10-02 2004-10-01 Compounds and compositions as protein kinase inhibitors

Country Status (9)

Country Link
US (2) US7569593B2 (fr)
EP (1) EP1670780A4 (fr)
JP (1) JP2007507540A (fr)
CN (1) CN100455579C (fr)
AU (1) AU2004275888B2 (fr)
BR (1) BRPI0414869A (fr)
CA (1) CA2540518A1 (fr)
MX (1) MXPA06003644A (fr)
WO (1) WO2005030151A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755592A1 (fr) * 2004-04-20 2007-02-28 AB Science Utilisation d'inhibiteurs de c-kit pour le traitement de troubles musculaires inflammatoires comprenant la myosite et la dystrophie musculaire
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
US8178526B2 (en) * 2007-06-15 2012-05-15 Irm Llc Compounds and compositions as ITPKb inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
WO2010095227A1 (fr) * 2009-02-19 2010-08-26 富士通株式会社 Nouveau composé et inhibiteur de liaison, agent antiallergique, agent contre l'asthme et agent anti-inflammatoire
JP5370472B2 (ja) * 2009-02-19 2013-12-18 富士通株式会社 新規化合物、並びに、結合阻害剤、抗アレルギー剤、抗喘息剤、及び抗炎症剤
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10687531B2 (en) 2016-07-22 2020-06-23 Syngenta Participations Ag Urea and thiourea substituted bicycles derivatives as pesticides
CN108103186B (zh) * 2018-02-28 2021-07-02 固安博健生物技术有限公司 诊断类风湿性关节炎和骨关节炎的分子标志物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
ATE263770T1 (de) * 1994-02-04 2004-04-15 Smithkline Beecham Plc Verfahren zum epoxidieren prochiral olefine
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
US6235760B1 (en) * 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
JP2000504023A (ja) * 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AU1623601A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Novel compounds
CA2423154A1 (fr) * 2000-09-21 2002-03-28 David Kenneth Dean Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
ES2289004T3 (es) 2000-11-20 2008-02-01 Smithkline Beecham Corporation Nuevos compuestos.
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CID 11271644, *
CID 11439958, *
CID 11471239 *

Also Published As

Publication number Publication date
US7569593B2 (en) 2009-08-04
CN100455579C (zh) 2009-01-28
MXPA06003644A (es) 2006-06-20
WO2005030151A3 (fr) 2005-09-09
JP2007507540A (ja) 2007-03-29
US20090258910A1 (en) 2009-10-15
US20050209285A1 (en) 2005-09-22
CA2540518A1 (fr) 2005-04-07
EP1670780A4 (fr) 2008-12-17
AU2004275888A1 (en) 2005-04-07
CN1860111A (zh) 2006-11-08
EP1670780A2 (fr) 2006-06-21
BRPI0414869A (pt) 2006-11-28
WO2005030151A2 (fr) 2005-04-07

Similar Documents

Publication Publication Date Title
AU2004278413B2 (en) Compounds and compositions as protein kinase inhibitors
US20090258910A1 (en) Compounds and compositions as protein kinase inhibitors
US8106068B2 (en) Compositions and methods for modulating c-kit and PDGFR receptors
US7449582B2 (en) Compounds and compositions as protein kinase inhibitors
AU2008247442B2 (en) Compounds and compositions as c-kit and PDGFR kinase inhibitors
ES2477878T3 (es) Compuestos y composiciones de 5-(4-(aloalcoxi)fenil)pirimidin-2-amina como inhibidores de quinasas
ES2368876T3 (es) Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa.
KR101280809B1 (ko) Vegf 수용체 키나제 억제제로서 안트라닐아미드피리딘우레아
JP2009511558A (ja) 癌の処置のためのピリミジン誘導体
KR20070083906A (ko) 혈관 내피 성장 인자 (vegf) 수용체 키나제 억제제로서신규 안트라닐아미드 피리딘우레아
JP2010512405A (ja) キナーゼ阻害剤としての化合物および組成物
KR20070085609A (ko) 혈관 내피 성장 인자 (vegf) 수용체 키나제 억제제로서니코틴아미드 피리딘우레아

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired